- Home
- GRI vs ONCO Comparison
GRI vs ONCO Comparison
Compare GRI & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- ONCO
- Stock Information
- Founded
- GRI 2018
- ONCO 2018
- Country
- GRI United States
- ONCO United States
- Employees
- GRI N/A
- ONCO N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- GRI Health Care
- ONCO Health Care
- Exchange
- GRI Nasdaq
- ONCO Nasdaq
- Market Cap
- GRI 4.3M
- ONCO 4.7M
- IPO Year
- GRI N/A
- ONCO 2022
- Fundamental
- Price
- GRI $1.64
- ONCO $2.68
- Analyst Decision
- GRI Strong Buy
- ONCO
- Analyst Count
- GRI 2
- ONCO 0
- Target Price
- GRI $22.50
- ONCO N/A
- AVG Volume (30 Days)
- GRI 175.4K
- ONCO 33.6K
- Earning Date
- GRI 11-14-2025
- ONCO 12-09-2025
- Dividend Yield
- GRI N/A
- ONCO N/A
- EPS Growth
- GRI N/A
- ONCO N/A
- EPS
- GRI N/A
- ONCO N/A
- Revenue
- GRI N/A
- ONCO $1,326,959.00
- Revenue This Year
- GRI N/A
- ONCO N/A
- Revenue Next Year
- GRI N/A
- ONCO N/A
- P/E Ratio
- GRI N/A
- ONCO N/A
- Revenue Growth
- GRI N/A
- ONCO N/A
- 52 Week Low
- GRI $1.10
- ONCO $2.45
- 52 Week High
- GRI $17.51
- ONCO $244.80
- Technical
- Relative Strength Index (RSI)
- GRI 41.46
- ONCO 33.93
- Support Level
- GRI $1.60
- ONCO $2.92
- Resistance Level
- GRI $1.79
- ONCO $3.99
- Average True Range (ATR)
- GRI 0.17
- ONCO 0.24
- MACD
- GRI -0.04
- ONCO -0.11
- Stochastic Oscillator
- GRI 7.25
- ONCO 0.61
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.